Sosei Heptares acquires Idorsia's pharma business in Japan and beyond

20 July 2023
sosei-large

The Sosei Group Corporation (TYO: 4565) has acquired Swiss biotech Idorsia’s (SIX: IDIA) pharma business in Japan and Asia Pacific, excluding China.

In those territories, the group - which goes by the brand name Sosei Heptares - picks up rights to a pipeline of medicines from Idorsia’s portfolio, with lead product Pivlaz (clazosentan) already commercially available and with fast-growing sales in Japan following a successful launch last year.

"A step change in delivering on our ambitious growth strategy"Another drug seen as having significant growth potential is daridorexant. A Japanese filing is expected next year for insomnia for a product that is marketed in the USA and Europe as Quviviq.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical